The magnitude of spontaneous IL-10 production by cultured CLL cells exhibited inter-patient variability (Supplementary Figure 4A) but was reduced significantly by ruxolitinib (Figure 2A). This evidence concerns the gene IL10 and B-cell chronic lymphocytic leukemia.